Research programme: mitochondrial therapeutics - Gencia/ Takeda
Alternative Names: GEN-3026Latest Information Update: 28 Apr 2022
At a glance
- Originator Gencia Biotechnology
- Developer Gencia Biotechnology; Takeda
- Class Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Inflammation; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA
- 28 Oct 2019 No recent reports of development identified for research development in Haematological-malignancies in USA
- 28 Oct 2019 No recent reports of development identified for research development in Inflammation in USA